THERAPEUTIC CLONING: LEGAL AND REGULATORY FRAMEWORK IN RUSSIA

1. INTRODUCTION

Therapeutic cloning refers to the use of somatic cell nuclear transfer (SCNT) or related cellular technologies to generate embryonic cellular material for scientific research and potential therapeutic applications. Its principal objective is to obtain genetically compatible cells for investigating disease mechanisms, regenerative medicine, and potential tissue-repair applications.

Therapeutic cloning raises significant legal and ethical questions concerning human embryo status, reproductive rights, human dignity, informed consent, biological material ownership, research oversight, and the distinction between therapeutic and reproductive cloning.

In Russia, therapeutic cloning must be examined within the broader framework of biomedical research, genetic engineering, human reproductive technologies, bioethics, and criminal law. Importantly, Russia does not have a comprehensive standalone statute specifically establishing a complete regulatory system for therapeutic cloning.

2. CONSTITUTIONAL AND LEGISLATIVE FRAMEWORK

A. CONSTITUTION OF THE RUSSIAN FEDERATION

The Constitution provides the fundamental legal principles relevant to biomedical research.

Article 20: Protects the right to life.

Article 21: Protects human dignity and prohibits treatment incompatible with human dignity.

Article 23: Protects privacy and personal and family confidentiality.

Article 41: Recognises the right to health protection and medical assistance.

Article 44: Protects freedom of scientific and other creative activities.

These constitutional provisions must be considered when evaluating the ethical and legal limits of cloning-related research.

B. FEDERAL LAW NO. 86-FZ OF 1996 ON STATE REGULATION IN THE FIELD OF GENETIC ENGINEERING ACTIVITIES

This legislation regulates relevant genetic engineering activities in Russia.

Its regulatory objectives include:

Establishing legal requirements for genetic engineering activities.

Protecting human health and the environment.

Establishing relevant biosafety responsibilities.

Providing a framework for state oversight of regulated genetic engineering activities.

Its application to a particular therapeutic cloning project depends on the technologies and activities involved. It should not be interpreted as a comprehensive therapeutic cloning authorization statute.

C. FEDERAL LAW NO. 323-FZ OF 2011 ON THE FUNDAMENTALS OF HEALTH PROTECTION OF CITIZENS IN THE RUSSIAN FEDERATION

This law establishes the general framework for healthcare, medical interventions, patient rights, and medical research.

Relevant provisions include:

Article 20: Informed voluntary consent to medical intervention.

Article 21: Choice of medical organisation and physician.

Article 22: Patient rights concerning medical information.

Article 36.1: Features of medical care using biomedical cell products.

These provisions are relevant to research and clinical applications involving cellular technologies.

D. FEDERAL LAW NO. 180-FZ OF 2016 ON BIOMEDICAL CELL PRODUCTS

This legislation provides a specialised regulatory framework for biomedical cell products.

It addresses matters including development, examination, production, circulation, and clinical application of regulated biomedical cell products.

Where therapeutic cloning research produces materials falling within the statutory definition of biomedical cell products, the applicable requirements must be examined.

E. FEDERAL LAW NO. 152-FZ OF 2006 ON PERSONAL DATA

This legislation becomes relevant where cloning research involves identifiable genetic information or personal biological data.

Research institutions must establish lawful grounds for processing personal data and implement appropriate confidentiality and security measures.

3. DISTINCTION BETWEEN THERAPEUTIC AND REPRODUCTIVE CLONING

Russian regulatory analysis must distinguish two different activities.

A. THERAPEUTIC CLONING

Therapeutic cloning involves the generation of embryonic cellular material for research or potential therapeutic purposes rather than the intended birth of a cloned individual.

Its legal assessment concerns embryo-related ethical questions, research authorization, biological material, cellular product regulation, and patient protection.

B. REPRODUCTIVE CLONING

Reproductive cloning involves attempting to produce a living individual through cloning technology.

Russia's Federal Law No. 54-FZ of 2002, concerning the temporary prohibition of human cloning, established a moratorium on human cloning. The original legislation contemplated a temporary prohibition and its duration and subsequent legal status must be assessed against later amendments and applicable legislation.

The distinction between therapeutic and reproductive cloning is therefore essential. A prohibition directed at human reproductive cloning should not automatically be treated as an express prohibition of every form of therapeutic cloning research.

4. REGULATORY AUTHORITIES AND INSTITUTIONAL RESPONSIBILITIES

Several Russian institutions may have responsibilities depending on the nature of the research:

Ministry of Health of the Russian Federation: Responsible for relevant healthcare policy and regulatory administration.

Federal Service for Surveillance in Healthcare (Roszdravnadzor): Exercises regulatory oversight within its statutory competence concerning healthcare and medical products.

Federal Medical-Biological Agency (FMBA): Performs specified healthcare and biomedical functions.

Research Ethics Committees: Review ethical acceptability and participant-protection issues within applicable institutional and regulatory arrangements.

Scientific Research Institutions: Must maintain appropriate research governance, documentation, biosafety, and ethical safeguards.

No single authority should be assumed to provide universal authorization for every therapeutic cloning activity.

5. ETHICAL AND LEGAL REQUIREMENTS

Therapeutic cloning raises several important legal and ethical considerations.

A. INFORMED CONSENT

Donors providing biological materials must receive appropriate information concerning the proposed research, intended use, confidentiality, and relevant risks.

B. EMBRYO PROTECTION

Research involving human embryonic material requires careful consideration of applicable legislation, ethical requirements, and institutional oversight.

C. REPRODUCTIVE CLONING RESTRICTIONS

Research activities must remain distinguishable from prohibited or restricted reproductive cloning activities.

D. GENETIC DATA PROTECTION

Genetic information must be handled according to applicable personal data and confidentiality requirements.

E. BIOMEDICAL PRODUCT SAFETY

Where resulting materials qualify as biomedical cell products, the applicable requirements under Federal Law No. 180-FZ must be observed.

6. SIX IMPORTANT JUDICIAL AUTHORITIES AND CASE LAWS

Russian reported judicial decisions specifically addressing therapeutic cloning are limited. The following authorities provide relevant constitutional, human-rights, medical, and analogous legal principles. They should not be represented as direct judicial rulings approving therapeutic cloning.

1. Constitutional Court of the Russian Federation, Judgment No. 2-P of 3 February 1998 – ANALOGOUS CONSTITUTIONAL AUTHORITY

This judgment concerned constitutional guarantees and the relationship between individual rights and state legal restrictions. Its broader constitutional principles are relevant when assessing the balance between scientific freedom, human dignity, and state regulation of biomedical research.

2. Constitutional Court of the Russian Federation, Judgment No. 11-P of 16 June 1998 – ANALOGOUS CONSTITUTIONAL AUTHORITY

This decision addressed constitutional questions concerning individual rights and legal safeguards. Its broader reasoning may inform the interpretation of fundamental rights in sensitive biomedical research.

3. European Court of Human Rights, Evans v. United Kingdom (2007) – ANALOGOUS BIOMEDICAL AUTHORITY

The case concerned reproductive material, consent, and competing reproductive interests. The Court examined the importance of consent in the use and preservation of reproductive biological material. Its principles are relevant to disputes involving biological material donation and research consent.

4. European Court of Human Rights, Parrillo v. Italy (2015) – ANALOGOUS EMBRYO-RESEARCH AUTHORITY

The case concerned restrictions on the donation of embryos created through in-vitro fertilisation for scientific research. The Court examined the relationship between private life, ownership arguments, and the state's regulatory discretion concerning embryos. This is particularly relevant to therapeutic cloning because it illustrates the legal complexity surrounding human embryonic material.

5. European Court of Human Rights, S.H. and Others v. Austria (2011) – ANALOGOUS REPRODUCTIVE TECHNOLOGY AUTHORITY

The case concerned restrictions on particular assisted reproductive technologies. The Court considered the relationship between reproductive autonomy, medical developments, and the state's margin of appreciation. Its reasoning is relevant to regulatory approaches towards emerging reproductive and cellular technologies.

6. European Court of Human Rights, Costa and Pavan v. Italy (2012) – ANALOGOUS GENETIC TECHNOLOGY AUTHORITY

The case concerned access to preimplantation genetic diagnosis in the context of reproductive healthcare. The Court considered the relationship between reproductive choices and private and family life. Its principles are relevant to the regulation of genetic technologies and reproductive biomedical research.

The European Court of Human Rights authorities require an important jurisdictional qualification: they are not Russian domestic judgments. Their relevance to Russia is interpretative and historical, and their applicability must account for Russia's withdrawal from the European Convention on Human Rights, effective 16 September 2022, and the temporal scope of the Convention.

7. REGULATORY CHALLENGES

Therapeutic cloning presents several important regulatory difficulties:

Uncertainty concerning the legal status of cloned embryonic material.

Distinguishing therapeutic research from reproductive cloning.

Establishing appropriate consent standards for biological material donation.

Determining institutional and governmental authorization requirements.

Protecting identifiable genetic and reproductive information.

Assessing the safety of resulting cellular products.

Establishing liability for research-related injuries.

Balancing scientific freedom with human dignity and ethical restrictions.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Russian research organisations undertaking relevant biomedical research should:

Determine whether the proposed research falls within applicable cloning restrictions.

Obtain appropriate institutional and regulatory approvals.

Establish documented informed-consent procedures.

Verify the legal status and permitted use of biological materials.

Implement appropriate ethical review.

Maintain genetic-data confidentiality and security.

Determine whether Federal Law No. 180-FZ applies to resulting cellular products.

Maintain appropriate biosafety and research records.

Prohibit unauthorized reproductive applications.

Establish procedures for monitoring research-related adverse events.

9. CONCLUSION

Therapeutic cloning regulation in Russia operates through a combination of constitutional protections, genetic engineering legislation, healthcare regulation, biomedical cell product legislation, and human cloning restrictions. Federal Laws No. 54-FZ, No. 86-FZ, No. 180-FZ, and No. 323-FZ are particularly important to understanding the regulatory environment.

The legal distinction between therapeutic and reproductive cloning remains fundamental. Russian law does not provide a single comprehensive statutory authorization framework for all therapeutic cloning research. Consequently, each project requires an independent assessment of its scientific purpose, biological materials, ethical acceptability, regulatory classification, and potential clinical application. The judicial authorities discussed above provide analogous principles concerning human dignity, informed consent, reproductive autonomy, and embryo-related research, rather than direct Russian judicial approval of therapeutic cloning.